In this study, we analyzed the therapeutic effects of a novel antibody, which selectively inhibits TNFR1 while retaining protective TNFR2 signaling in a high-fat diet (HFD) mouse model of NAFLD. This evidence concerns the gene TNFRSF1A and metabolic dysfunction-associated steatotic liver disease.